Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability.
Yu KL, Sin N, Civiello RL, Wang XA, Combrink KD, Gulgeze HB, Venables BL, Wright JJ, Dalterio RA, Zadjura L, Marino A, Dando S, D'Arienzo C, Kadow KF, Cianci CW, Li Z, Clarke J, Genovesi EV, Medina I, Lamb L, Colonno RJ, Yang Z, Krystal M, Meanwell NA.
Yu KL, et al.
Bioorg Med Chem Lett. 2007 Feb 15;17(4):895-901. doi: 10.1016/j.bmcl.2006.11.063. Epub 2006 Dec 1.
Bioorg Med Chem Lett. 2007.
PMID: 17169560